arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

download Export Data

HeartSciences Inc.

HSCS

$4.57 ▼ -0.01 (-0.33%) at close

6 Visible periods

25 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, HeartSciences Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $12.0M

Dividend Yield —

Revenue Growth -0.7% ↗

Op. Margin —

ROIC -3239.3% →

FCF / Share $-2.83 ↗

Trailing P/E —

Price / Book 24.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$4.32K

↓ -0.7% —

Net Income Profit after all expenses

$-9.14M

↓ -4.3% —

FCF / Share Free cash flow per share

$-2.83

↑ +64.2% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -3239.3% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of 0.81x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

$0.00

FY 2026

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗
Revenue Growth YoY (%)	-0.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-109%)	-76.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1058%)	261.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3165%)	-64.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-902%)	—	—
EPS Growth YoY (%)	62.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	50.8% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	76.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	44.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-4.3% Weak ↑ Weak Improving Year-over-year change in net income	-32.7% Weak ↓ Weak Declining Year-over-year change in net income	-3.9% Weak Weak Year-over-year change in net income	-31.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	64.2% Excellent Excellent Year-over-year change in free cash flow	54.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	-5.7% Weak Weak Compound annual revenue growth over 3 years	-32.9% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗
FCF / Net Income (x)	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗
Return on Invested Capital (%)	-3239.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-3216.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-68.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-2094.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	61.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-199.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-197.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-66.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-186.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-225.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	-90.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-702%)	—	79.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+432%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗
Interest Coverage (x)	—	—	-17.81x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-25.14x Weak Weak Operating income divided by interest expense Optimal: > 5x	-12.67x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-1.10M	$-1.10M	$-5.81M	$-1.66M	$-918.26K	—

📊 What does each share earn? 8 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.05	—	$0.43	—
Basic EPS, GAAP (USD)	$-3.48	$-9.34	$-19.00	$-80.00	$-145.00	—
Free Cash Flow per Share (USD)	$-2.83	$-7.90	$-17.40	—	$-109.86	—
Dividend per Share (USD)	$0.00	—	—	—	—	—
Book Value per Share (USD)	$0.18	$0.18	$10.81	$2.28	$-182.19	—
Tangible Book Value per Share (USD)	$0.18	$0.18	$10.81	$2.28	$-182.19	—
Basic Weighted Avg Shares (shares)	2.63M	938,257	352,520	79,506	33,189	—
Dividend Payout Ratio (%)	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗
Working Capital (USD)	$-1.53M	$-1.53M	$5.60M	$863.69K	$-1.54M	—
Total Equity (USD)	$205.17K	$205.17K	$7.32M	$230.56K	$-6.06M	$-1.91M

📋 What is driving earnings? 4 metrics

Metric	FY 2026 Apr 30, 2026 10-K ↗	FY 2025 Apr 30, 2025 10-K ↗	FY 2024 Apr 30, 2024 10-K ↗	FY 2023 Apr 30, 2023 10-K ↗	FY 2022 Apr 30, 2022 10-K ↗	FY 2021 Apr 30, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$4.32K	$4.35K	$18.60K	$5.15K	$14.37K	—
Depreciation Expense (USD)	$27.79K	$37.60K	$27.89K	$26.91K	$26.57K	—
Net Income, GAAP (USD)	$-9.14M	$-8.77M	$-6.61M	$-6.35M	$-4.83M	—
Operating Cash Flow (USD)	$-7.43M	$-7.41M	$-6.07M	$-5.77M	$-3.64M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 22 quarters

HeartSciences Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare HSCS with peers